This Dollar Tree Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts rated Lycia Outperform ($43), Comfort Systems Overweight ($1,410), BlackRock Outperform ($1,450), and Dollar Tree/Kroger Buy ($160/$80).
Last updated: 2026-11-18 20:54:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Lycia Therapeutics, Inc. (LYCA) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $31.27, with a market capitalization of $1.49B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.19 to $36.49. This page covers its latest market performance, valuation, price trends and company information.
$1.49B | |
$30.60 | |
$32.55 | |
$30.46 | |
$30.92 | |
328.92K | |
444.64K | |
-- | |
$36.49 | |
$22.19 | |
-- | |
2026-06-30 |
Lycia Therapeutics, Inc. (LYCA) is currently trading at $31.27 as of 2026-11-18 20:53:00, up 0.02% ($0.00) from the previous close of $30.92
During today's regular trading session, LYCA has traded between $30.46 and $32.55, with a trading volume of 328.92K shares. The current price is near the middle of today's range.
LYCA is up 0.33% during regular trading hours.
Over the past seven days, Lycia Therapeutics, Inc. (LYCA) moved from $30.36 to $31.27, representing a gain of 3.01% ($0.91).
The stock traded between $28.18 and $33.56 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 312.33 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 63.5%
LYCA is currently trading at $31.27, placing it 63.5% of the way from its 52-week low of $22.19 to its 52-week high of $36.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lycia Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.
| Exchange | NASDAQ |
| Company Website |
Latest news related to Lycia Therapeutics, Inc. and LYCA stock.
Analysts rated Lycia Outperform ($43), Comfort Systems Overweight ($1,410), BlackRock Outperform ($1,450), and Dollar Tree/Kroger Buy ($160/$80).
Jefferies analyst Faisal Khurshid initiates coverage on Lycia Therapeutics (NASDAQ:LYCA) with a Buy rating and announces Price Target of $50.
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Lycia Therapeutics (NASDAQ:LYCA) with a Outperform rating and announces Price Target of $43.
Eligible investors can buy real shares of Lycia Therapeutics, Inc. (LYCA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LYCA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LYCA shares and USD.
LYCA Shares to USD
1.00 LYCA shares = 31.274 USD
Calculations are estimates based on the latest available price and are for reference only.